Aspergillus endocarditis in a native valve after amphotericin B treatment.
Systemic infection with Aspergillus fumigatus is an opportunistic disease that affects mainly immunocompromised hosts and is associated with a high mortality rate. We report a case of A. fumigatus endocarditis after an episode of thrombotic thrombocytopenic purpura. Diagnosis was established after sudden rupture of posterior papillary muscle of the normal native mitral valve. Soon after mitral valve replacement, Aspergillus endocarditis recurred, associated with multiple peripheral emboli, which necessitated a second operation.
Department of Critical Care and Pulmonary Services, University of Athens, Athens, Greece. akotanid@med.uoa.gr
Anastasia N
AN
Kotanidou
Epaminonthas
E
Zakynthinos
Ilias
I
Andrianakis
Dimitrios
D
Zervakis
Ioannis
I
Kokotsakis
Theodoros
T
Argyrakos
Athina
A
Argiropoulou
Georgia
G
Margariti
Emmanuel
E
Douzinas
D000666:Amphotericin B / Q000494:pharmacology / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery; D001232:Aspergillus fumigatus / Q000187:drug effects / Q000302:isolation & purification*; D002177:Candidiasis / Q000150:complications / Q000188:drug therapy; D025141:Drug Resistance, Fungal; D004617:Embolism / Q000209:etiology; D004696:Endocarditis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery; D017809:Fatal Outcome; D005260:Female; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D017964:Itraconazole / Q000627:therapeutic use; D008172:Lung Diseases, Fungal / Q000150:complications / Q000188:drug therapy; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000000981:diagnostic imaging / Q000209:etiology* / Q000382:microbiology / Q000601:surgery; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology* / Q000601:surgery; D010210:Papillary Muscles; D011183:Postoperative Complications / Q000382:microbiology; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000150:complications; D011697:Purpura, Thrombotic Thrombocytopenic / Q000150:complications*; D012008:Recurrence; D012422:Rupture, Spontaneous; D012772:Shock, Septic / Q000209:etiology / Q000382:microbiology; D013183:Sputum / Q000382:microbiology; D014463:Ultrasonography; D014552:Urinary Tract Infections / Q000150:complications / Q000188:drug therapy / Q000382:microbiology
D000890:Anti-Infective Agents; D007166:Immunosuppressive Agents; D017964:Itraconazole; D000666:Amphotericin B; D011239:Prednisolone